| Wissenschaftl. Titel | A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE). |
| Erkrankung |
Gyn:
Mamma-Ca:
Alle Linien
|
| Kurzprotokoll | Kurzprotokoll |
| Links | Weiterführende Informationen (M) Weiterführende Informationen (NIH) |
erstellt 14.01.2019 Data entry IX CCP
geändert 27.01.2021 Data entry IX CCP